Sapio Sciences makes AI-Native drug discovery seamless with NVIDIA BioNeMo

Sapio Sciences has integrated the NVIDIA BioNeMo platform into its science-aware™ Lab Informatics Platform, bringing AI-driven computational drug discovery capabilities directly into the Sapio ELN (Electronic Lab Notebook). This advanced integration empowers researchers to streamline their workflows, make data-driven decisions, and accelerate the discovery and development of potential drug candidates.

By leveraging NVIDIA BioNeMo's science-specific AI frameworks, pre-trained models, and generative AI tools, scientists can enhance their research efficiency and accuracy. The platform enables early-stage generation of novel candidate molecules and predictive docking with target proteins — all within a unified, AI-powered workflow.

Within Sapio ELN, researchers can access BioNeMo NIM microservices to optimize drug candidates through AI-driven molecular modeling, including:

AlphaFold2 NIM: Predicts accurate 3D protein structures.
MoIMIM NIM: Supports the design and optimization of small molecules.
DiffDock NIM: An AI-powered docking model from MIT for faster and more accurate docking simulations.

This seamless integration eliminates complex setups, allowing scientists to focus on groundbreaking discoveries while enhancing research precision.

Kevin from Sapio Sciences stated, "Partnering with NVIDIA enables us to integrate the most advanced AI tools for life sciences research. This collaboration marks a significant step toward making AI central to drug discovery, helping researchers achieve faster, more accurate results."

Anthony Costa, Director of Digital Biology at NVIDIA, added, "The integration of BioNeMo into Sapio’s platform empowers scientists with AI-driven capabilities for faster, more precise drug discovery. This effort showcases AI's transformative role in accelerating pharmaceutical research and breakthrough treatments."

Sapio Sciences continues to innovate, driving efficiency and accuracy in biopharma discovery, clinical diagnostics, and drug manufacturing through advanced AI solutions.

Source: Business Wire